Vaxess - About the company
Vaxess is a series D company based in Cambridge (United States), founded in 2011 by Michael Schrader and Kathryn Kosuda. It operates as a Developer of novel vaccine formulations using silk stabilization platform. Vaxess has raised $117M in funding from investors like RA Capital Management, Norwich Ventures and Engine. The company has 3460 active competitors, including 1128 funded and 793 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.
Company Details
Developer of novel vaccine formulations using a silk stabilization platform. Technology includes extracting fibroin from silk in which biological compounds are encapsulated to provide heat stability. It is also developing product formats that enable novel routes of administration like microneedles for transdermal applications. It has developed MIMIX therapies that help in treating cancers such as skin cancers, breast cancer, and infectious diseases.
- Website
- vaxess.com/
Key Metrics
Founded Year
2011
Location
Cambridge, United States
Stage
Series D
Total Funding
$117M in 30 rounds
Latest Funding Round
Investors
Ranked
39th among 3460 active competitors
Employee Count
129 as on Sep 30, 2026
Similar Companies
Sign up to download Vaxess' company profile
Vaxess's funding and investors
Vaxess has raised a total funding of $117M over 30 rounds. Its first funding round was on Apr 25, 2012. Vaxess has 18 institutional investors.
Here is the list of recent funding rounds of Vaxess:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 27, 2025 | 2070214 | Series D | 2363339 | 9383942 | 1481051 | 3888986 |
Feb 14, 2025 | 2987672 | Series D | 3021188 | 6947433 | 1998185 | |
Sep 16, 2024 | 4771549 | Grant (prize money) | 5536474 | 9555843 | 9595833 |
View details of Vaxess's funding rounds and investors
Vaxess' founders and board of directors
Founder? Claim ProfileThe founders of Vaxess are Michael Schrader and Kathryn Kosuda.
Here are the details of Vaxess' key team members:
- Michael Schrader: Co-Founder and CEO of Vaxess and founder of 1 other company.
- Kathryn Kosuda: Co-Founder of Vaxess and founder of 1 other company. Contact Info: 1 email address
View details of Vaxess's Founder profiles and Board Members
Vaxess' employee count trend
Vaxess has 129 employees as of Sep 26. Here is Vaxess's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Vaxess's Competitors and alternates
Top competitors of Vaxess include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Vaxess, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 77/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th | Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
5th | Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 72/100 | |
6th | Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
7th | Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
8th | Relay Therapeutics 2016, Cambridge (United States), Public | Developer of drug discovery platform and study protein motion | $520M | 71/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
39th | Vaxess 2011, Cambridge (United States), Series D | Developer of novel vaccine formulations using silk stabilization platform | $117M | 67/100 |
Looking for more details on Vaxess's competitors? Click here to see the top ones
Vaxess's Investments and acquisitions
Vaxess has made no investments or acquisitions yet.
Reports related to Vaxess
Here is the latest report on Vaxess's sector:
News related to Vaxess
Media has covered Vaxess for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
Terrestrial Bio Leases 42,000 SF for HQ at King Street’s Allston Labworks in BostonCRE Market Beat•Mar 26, 2026•Vaxess
•
Microneedle vaccine patch company Terrestrial Bio raises $50M for GLP-1 deliveryEndpoints•Mar 25, 2026•Vaxess, Engine Ventures, Global Health Investment, SiteGround and 1 other
•
Vaxess Inks $9M Funding RoundMassinvestor•Apr 25, 2025•Vaxess, RA Capital Management, Engine Ventures
•
Newmark recruits senior duo to UK student homes and build-to-rent investmentCoStar•Mar 24, 2025•Newmark, Vaxess
•
Vaxess Technologies has filed a notice of an exempt offering of securities to raise $12,000,000.00 in New Debt Financing.https://www.intelligence360.news/•Jun 10, 2024•Vaxess
•
•
Vaccine patch maker Vaxess raises $12M, names new CEODrug Delivery Business•May 22, 2024•Vaxess, RA Capital Management, Engine Ventures, Mission BioCapital and 5 others
•
Vaxess Technologies Raises $9M in FundingFinSMEs•Sep 13, 2023•Vaxess, RA Capital Management, Engine, Global Health Investment and 1 other
•
AstraZeneca and Vaxess developing skin patch mRNA vaccines for pandemic fluEndPoints News•Aug 24, 2023•AstraZeneca, Vaxess
•
Vaccine patch maker Vaxess names former Sanofi exec as chief strategy officerDrug Delivery Business•Mar 22, 2023•Vaxess, Sanofi
Are you a Founder ?
FAQs about Vaxess
Explore our recently published companies
- VEINLAND - Seddiner See based, 2006 founded, Unfunded company
- Vantec - Webster City based, 1983 founded, Acquired company
- Unique Instruments - Bengaluru based, 1995 founded, Funding Raised company
- Paramountlooms - 2015 founded, Unfunded company
- Perfecto Tool - Anderson based, 1955 founded, Funding Raised company
- Artechinfra - India based, Unfunded company